Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
With a market cap of 491.76B, Johnson & Johnson(JNJ) trades at $204.20. The stock has a price-to-earnings ratio of 19.60 and currently yields dividends of 2.5%.
On 2025-11-22, Johnson & Johnson(JNJ) stock traded between a low of $202.99 and a high of $206.94. Shares are currently priced at $204.20, which is +0.6% above the low and -1.3% below the high.
Johnson & Johnson(JNJ) shares are trading with a volume of 13.19M, against a daily average of 10.33M.
In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $206.94 and a 52-week low of $140.68.
In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $206.94 and a 52-week low of $140.68.
JNJ News
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
Looking at the universe of stocks we cover at Dividend Channel, on 11/25/25, Vertiv Holdings Co (Symbol: VRT), Primo Brands Corp (Symbol: PRMB), and Johnson & J...
This week's dividend activity included increased payouts from Merck (MRK) and Nike (NKE) as well as declarations from companies such as Nvidia (NVDA) and Home D...
Analyst ratings
57%
of 28 ratingsMore JNJ News
Wondering if Johnson & Johnson’s stock could actually be worth more than what the market is pricing in? You’re not alone. Today we’ll take a friendly but forens...
The Food and Drug Administration announced traditional approval of Johnson & Johnson’s Darzalex Faspro with bortezomib, cyclophosphamide, and dexamethasone for...
Key Points J&J beat Wall Street estimates on sales and profits in the third quarter. The company recently announced the acquisition of a biotech with an innov...
In November 2025, Johnson & Johnson announced several significant milestones, including FDA approvals for new indications of DARZALEX FASPRO® and CAPLYTA, as we...
Hedge funds appear to be rebuilding their defensive playbook, and perhaps the clearest tell is a subtle but broad rotation into heavyweight healthcare names. Re...
Johnson & Johnson (NYSE:JNJ) on Monday agreed to acquire Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. Halda is a clinical-stage biotechnology compa...
Shares in medtech giant Johnson & Johnson (JNJ) rose today as it said it would revolutionize cancer treatment following its $3.05 billion acquisition of “hold a...